

2020 Annual General Meeting Antipodes Global Investment Company Limited (ASX: APL)

30 November 2020



Agenda

Chairman's Address
Formal Business
Investment Update and Q&A



Mr Jonathan Trollip

Overview

- APL (Company) offers Shareholders access to a long-short global securities investment portfolio with a currency overlay
- Company has net assets of \$520 million* and listed on the ASX on 18 October 2016

- Managed by Antipodes Partners Limited (Manager)
- The Manager aims to build portfolios with a capital preservation focus
- The Manager seeks to purchase securities in what it considers to be great businesses that are not valued as such, and build a high conviction portfolio

Investment Objectives

- 1. provide capital **growth and income** through investing in a concentrated Portfolio, predominantly comprised of Long and Short Positions in international listed securities, that will be actively managed with a **focus on capital preservation**; and
- 2. achieve returns in excess of the Benchmark, with reduced levels of risk



Company Details

Manager

Antipodes Partners Limited

Board of Directors


- Jonathan Trollip (Chairman)
- Lorraine Berends
- Chris Cuffe
- Alex Ihlenfeldt
- Andrew Findlay

Shares ¹ (ASX: APL)					
Outstanding	477,221,507				
Price	\$0.955				
Market capitalisation	\$456m				
NTA					
Pre-tax NTA (Which includes tax provided for on realised gains) ²	\$1.091				
Post-tax NTA (Which includes tax provided for on realised and unrealised gains) ³	\$1.089				



Dividends


- FY20 Final dividend of 2.5 cents per share, franked as to 50%
- The full FY20 financial year dividend is 4.5 cents per share (50% franked) which equates to an annual yield of 4.7%² and a grossed-up yield of 5.7%³, a strong level of income for a global equity portfolio



FY2020 Final Dividend				
Amount	2.5 cents per share			
Ex-dividend Date	8 Sept 2020			
Dividend Record Date	9 Sept 2020			
Dividend Payment Date	30 Sept 2020			



NTA Movements since IPO



Source: Antipodes Partners

^{*} Values represented are the estimated cents per share impacts calculated using aggregated yearly values for each financial year since inception. Portfolio performance is after management and performance fees.



^{**} Pre-tax NTA includes provision for tax on realised gains / losses and other earnings, but excludes any provision for tax on unrealised gains / losses and deferred tax assets relating to capitalised issue costs and income tax losses.

Performance

Company Performance¹

- 6.5% annualised from listing date to 31 October 2020
- Underperformance vs benchmark since inception primarily driven by CY2019 performance

Periodic Performance² as at 31 October 2020

	Company	MSCI AC World Net Index	Difference		
3 month	3.2%	2.3%	0.8%		
1 year	(1.0%)	2.9%	(3.9%)		
3 year p.a.	3.0%	8.7%	(5.6%)		
Inception p.a.	6.5%	11.3%	(4.8%)		

TSR Performance²

 -0.1% annualised from listing date to 31 October 2020 (share price of \$0.955 compared to an issue price of \$1.10, with dividends paid since inception of \$0.14)

NTA discount

Based on the pre-tax NTA on 25 November 2020 of \$1.189 per share and the closing share price on that date of \$1.075
per share, APL shares are trading at a 10.0% discount to NTA



Initiatives to close the discount to NTA

Shareholder alignment

Ownership by Antipodes & staff > 11 million shares, a top 10 Shareholder

Transparency & communication

Daily NTA; Increased Shareholder communication

Market support

Top 10 most liquid LIC; Highly Recommended Zenith; Coverage by broker research teams

Capital management

- Conditional Tender Offer Significant new initiative
- On Market Buy-Back
 - 13.5% of the Company's shares repurchased¹ at an average NTA discount in excess of 14%.
 - 39.6 million shares remain under existing on market buy-back authority (8.3% of current shares in issue)²
- 4.7%³ Dividend Yield (pre franking)



¹ Based on 74.3 million shares purchased since 1 August 2019 to 31 October 2020



² As at 31 October 2020

³ Based on 31 October 2020 share price of \$0.955

Shareholder Engagement



Regular shareholder emails



New website antipodespartners.com/apl/



Daily NTA announcement , monthly and quarterly updates





Half & full year financial results



Conference presentations





Mr Jonathan Trollip

Financial statements and reports

Consideration of financial statements and reports



Resolution 1

Adoption of the Remuneration Report

To consider and, if thought fit, to pass the following resolution:

"That the Remuneration Report of the Company for the financial year ended 30 June 2020 be adopted."



Resolution 1 - Proxies

Shares Voted

For	84,308,418	94.33 %
Open	2,522,943	2.82 %
Against	2,549,448	2.85 %
Abstain	185,	634



Resolution 2

Re-election of Chris Cuffe AO as a director

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That Mr Chris Cuffe AO, who retires by rotation in accordance with rule 6.7 of the Company's Constitution and, being eligible, offers himself for re-election, be re-elected as a director of the Company."



Resolution 2 - Proxies

Shares Voted

For	86,132,449	95.84 %
Open	2,608,071	2.9 %
Against	1,128,476	1.26 %
Abstain	12,	594



Resolution 3

Re-election of Jonathan Trollip as a director

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That Mr Jonathan Trollip, who retires by rotation in accordance with rule 6.7 of the Company's Constitution and, being eligible, offers himself for re-election, be re-elected as a director of the Company."



Resolution 3 - Proxies

Shares Voted

For	85,935,304	95.63 %
Open	2,623,071	2.92 %
Against	1,300,021	1.45 %
Abstain	23,1	194



Resolution 4

Approval of Conditional Tender Offer via an Equal Access Share Buy-Back

Conditional Tender Offer (CTO) Summary - Significant initiative to close the NTA discount

- AGM today to vote on the conditional tender offer via the "2021 Buy-Back".
- If the 2021 buy-back takes place, Shareholders will have the opportunity to tender their shares for sale to the Company via an **off-market buy-back**. The maximum number of shares the Company can buy-back will be **25%** of the shares on issue at that time. Any Shareholders wishing to sell >25% of their shares could have amounts in excess of 25% scaled back pro-rata to their shareholding (i.e. not pro-rata to how much they over tender).
- The buy-back will take place if the Company's closing share price exceeds a **7.5% discount to pre-tax NTA** for that same day on a daily average basis over the **12-month period ending 18 October 2021**.
- The buy-back price will be the average **post-tax NTA less 2%** as calculated over the period (less than 5 days) required to liquidate the portfolio post the closing of the buy-back offer period.



Resolution 4

Approval of Conditional Tender Offer via an Equal Access Share Buy-Back

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That, for the purposes of clause 2.7(b) of the Constitution, section 257C(1) of the Corporations Act 2001 (Cth) and for all other purposes, approval is given for the Company to buy back up to 25% of the Company's fully paid ordinary shares on the terms and conditions set out in the Explanatory Memorandum."



Resolution 4 - Proxies

Shares Voted

For	86,522,859	96.75 %
Open	2,618,651	2.93%
Against	289,555	0.32 %
Abstain	450	,525





Investment Manager Update

Antipodes Global Long-Short thematic clusters

Income/ Social Stimulus

Social commerce EM

Alibaba
JD.com, Tencent
Wester 7.8%

Social commerce/Software Incumbents DM

Facebook, Microsoft 9.0%

Pharma with pipeline

Merck Roche, Sanofi 8.3%

Reopening

Consumer franchises EM

Yum China
Ping An, HDFC Bank
12.7%

Consumer franchises DM

Capital One, ING Coca-Cola, Lowe's 17.3% Travel, Autos, Energy

GE, VW CNOOC 12.8%

Investment Stimulus

Connectivity/Compute

TSMC, Qualcomm Samsung Electronics 12.1%

Decarbonisation

Green capex EDF, Norsk Hydro 9.6%

Infrastructure

Siemens Shin-Etsu 5.1%

Tail Risk Protection

Tail risk credit (5.1%)


Tail risk equity (1.3%)

Gold 1.7% Single stock shorts (10.7%)



Global valuation clustering

Stark contrast between long and short duration equities



As at Sep 2020
Composite of forward PE, EV/Sales, EV/Operating Capital Employed (including goodwill) and cyclically adjusted PE and EV/EBIT for industrials, with EV based measures replaced with PB and cyclically adjusted P/Pre-provision profits for financials
Source: Antipodes Partners




Vaccines: key to Western 'normalization', EUA approvals likely by end 2020 in US

'First generation' vaccine data solid so far, 'Second generation' may provide longer protection

Pfizer & Moderna lead 1st generation vaccines; both >90% effective, safe so far

Potential Emergency Use Authorisation (EUA) in the US by end 2020 for both

1st generation vaccines may require boosting; not ideal for AstraZeneca & JNJ approaches 2nd generation vaccines may have stronger/longer protection. Sanofi/GSK adjuvant approach is attractive



Mass availability starting mid-2021; vaccine capacity of >6bn doses through 2021 across the major vaccine developers (1st and 2nd generation), US has pre-ordered >800m doses


Timeline sources: Company Announcements, Antipodes estimates



On the cusp of regime change

As COVID-19 accelerates a shift toward fiscal activism

- Reopening/vaccines, excess savings and pent up demand from lockdown
- · Supply chains 'moving home'
- Government directed spending e.g. decarbonisation, tech infrastructure, healthcare, social
 - → higher levels of real growth, shift in investment preferences, volatility in inflation
 - → higher real rates



Source: FactSet A tailwind for 'Value' and a headwind for overvalued/weaker 'Growth' businesses



Western Reopening exposure 30%: great companies in neglected sectors

Vaccines will accelerate recovery but not all behavior will "normalise", avoid value traps

Retail banking 6.8%













Travel 4.4%

Autos/Energy 8.4%









13 November 2020 Exposures are representative of Antipodes' Global Long-Short strategy



Emerging Markets Reopening exposure 20%: playing the long game

Opportunities in low AND high income brackets

Social commerce 7.8%

Consumer 8.1%

Retail banking 4.6%













13 November 2020
Exposures are representative of Antipodes' Global Long-Short strategy



Investment Stimulus exposure 27%: a different investment cycle is emerging

Decarbonisation alone set to contribute +2.1% GDP p.a. to Europe over the next decade

Connectivity/Compute 12.1%

Decarbonisation 9.6%

Infrastructure 5.1%













13 November 2020 Exposures are representative of Antipodes' Global Long-Short strategy



Summary: geopolitical risk driving domestic focus


Investment stimulus required for sustainable recovery

- Stimulus inflated initial COVID-19 beneficiaries → look for re-opening and investment-led stimulus beneficiaries
- Life won't automatically revert to pre-COVID status quo
 - De-globalisation will accelerate → consumption and supply chain re-localisation
 - Office demand/business travel may not mean revert, travel/retail shakeout → omnichannel survivors
- China's GDP rebounding faster, Europe has more sensitivity via the export channel
 - Europe arguably has more sensitivity to reopening/vaccines due to greater dependence on tourism
 - USD has lost real yield support, rallies should be sold
- Risk to recovery
 - US withdraws income stimulus before it reaches consensus on infrastructure stimulus
 - Social discontent/populism continues to intensify → higher taxes/more socialist policies
 - Open-ended fiscal deficits/government debt in US, Southern Europe → currency devaluation/inflation
 - China-US tech rivalry tempered by both sides' dependency on Taiwan/Korea, Mutually Assured
 Destruction mitigates the tail risk → stress test companies with large profit pools in both countries
 - Higher degree of diversification in DM reopening and investment stimulus clusters protects against near term uncertainty



Portfolio v benchmark weights and valuations

Tilt towards North American/European quality cyclicals and China/EM consumption



Source: iShares, FactSet, Antipodes

Portfolio and benchmark weights as of 30th Sep 2020.

Prices used in the PE multiples as of 30th Sep 2020.

Global Cyclicals = Commodities, Chemicals, Industrials, Autos/other durables, Hardware; Global Defensive = Internet, Software, Staples, Pharmaceuticals; Domestic = Retail, Housing & Construction, Media, Transport, Consumer/commercial services, Financials, Communications, Infrastructure, REITS



Performance

Performance to 31 Oct 2020	Company ¹	Benchmark ²	ACWI Value⁴
Quarter to date	2.0%	(0.4%)	(0.4%)
1 year	(1.0%)	2.9%	(13.9%)
3 year p.a.	3.0%	8.7%	0.5%
Inception ³ p.a.	6.5%	11.3%	4.6%

Past performance is not a reliable indicator of future performance.

⁴ MSCI All Country World Value Net Index



¹ Movement in NTA before tax for the period, adjusted for dividends and income taxes paid and the dilutionary effect of options granted to shareholders upon the Company's initial listing. This figure incorporates underlying portfolio performance net of portfolio related fees and costs, less administration costs of the Company.

² MSCI All Country World Net Index in AUD (underlying portfolio benchmark).

³ Inception date of the portfolio is 11 October 2016.

Global factors: performance and valuation

Growth, Profitability & Momentum have rarely been more expensive

Global factor performance*

Inception p.a. 2020 YTD1 2010-19 p.a **Factors** 2018-19 p.a. Value (25.7%)(5.9%)(4.1%)(0.3%)Growth 5.0% 8.4% 8.7% 0.6% Profitability 15.6% 10.2% 12.0% 5.0% Resilience 11.7% (2.0%)1.8% (0.3%)Momentum (12m) 27.3% 4.0% 2.0% 4.9%

Factors returns measure global price performance of the highest to lowest quintile (cheapest to most expensive for Value).


¹ As at June 30th 2020.



^{*}Cumulative price performance of long low multiple/high growth and short high multiple/low growth strategies. Common currency terms.

Source: FactSet, Antipodes

Sector-neutral composite valuation (30Y z-score)




Factor valuations are a ratio of the median multiple of the highest to lowest quintile (cheapest to most expensive for Value) and expressed as a Z-Score. Factor valuations are measured across sectors and averaged to remove the distorting effects of any one sector to a regional aggregate. Our approach to measuring multiples comprises an equal weighted composite of EV/CE, EV/Sales, forward PE and EV/normalised EBIT (P/B, forward PE, and P/normalised pre-provision profits for financials)
As at Sep 2020.



Performance vs Value peers and benchmark

Investment Growth



Trailing Returns

As of Date: 31/10/2020 Currency: Australian Dollar

	1 Month	3 Month	CYTD	1 Year	2 Years p.a.	3 Years p.a.	Since Inception p.a. (1/11/2016)	Inception (1/11/2016)
Antipodes Global Long-Short Strategy	2.1	3.1	-3.0	-0.3	0.8	3.2	6.8	30.2
Australia Fund Equity World Large Value	0.2	1.5	-12.9	-9.7	0.0	1.4	5.8	25.1
MSCI ACWI Value NR	-0.4	0.6	-16.5	-13.9	-2.1	0.5	4.9	21.1
MSCI ACWI NR	-0.4	2.3	-1.0	2.9	9.2	8.7	11.9	56.8

Performance data for the Antipodes Global Fund (ARSN 087 719 515) (the Fund) was provided to Morningstar Director for their analysis of Antipodes Partners Limited's (Antipodes) global long-short strategy. The Fund is managed by Antipodes applying the same investment strategy as it applies to the investment portfolio of Antipodes Global Investment Company Limited (ASX:APL).

The following charts and information are provided to compare the performance of Antipodes' global long-short strategy to the value index and other value-oriented peers as selected by Morningstar Direct.

Please note that the performance of the Fund differed from the performance of APL's NTA by an amount of 3.4% since inception due to differences in management fees, taxes, costs and portfolio position weights.

Source: Morningstar Direct

As at Oct 2020


Note: For track record comparability, Class I returns are used for the Antipodes Global Fund - Long.



Investment style and size bias vs Value peers

Holdings-Based Style Trail

Time Period: 31/10/2016 to 31/10/2020



Antipodes Global Long-Short Strategy
 Australia Fund Equity World Large Value
 MSCI ACWI Value NR
 MSCI ACWI NR
 31/10/2016
 31/10/2020
 MSCI ACWI NR
 31/10/2016
 31/10/2020

Performance data for the Antipodes Global Fund (ARSN 087 719 515) (the Fund) was provided to Morningstar Director for their analysis of Antipodes Partners Limited's (Antipodes) global long-short strategy. The Fund is managed by Antipodes applying the same investment strategy as it applies to the investment portfolio of Antipodes Global Investment Company Limited (ASX:APL).

The following charts and information are provided to compare the performance of Antipodes' global long-short strategy to the value index and other value-oriented peers as selected by Morningstar Direct.

Please note that the performance of the Fund differed from the performance of APL's NTA by an amount of 3.4% since inception due to differences in management fees, taxes, costs and portfolio position weights.

Source: Morningstar Direct


As at Oct 2020

Note: For track record comparability, Class I returns are used for the Antipodes Global Fund - Long.



Performance vs Value peers and benchmark

Drawdown



Drawdown

Time Period: 1/11/2016 to 31/10/2020 Currency: Australian Dollar

	Max Drawdown	Max Drawdown # of Periods	Max Drawdown Peak Date	Max Drawdown Valley Date	Up Capture Ratio	Down Capture Ratio
Antipodes Global Long-Short Strategy	-7.2	5.0	1/02/2020	30/06/2020	63.8	70.6
Australia Fund Equity World Large Value	-17.3	2.0	1/02/2020	31/03/2020	81.0	116.9
MSCI ACWI Value NR	-18.2	6.0	1/02/2020	31/07/2020	80.1	123.3
MSCI ACWI NR	-13.0	2.0	1/02/2020	31/03/2020	100.0	100.0

Performance data for the Antipodes Global Fund (ARSN 087 719 515) (the Fund) was provided to Morningstar Director for their analysis of Antipodes Partners Limited's (Antipodes) global long-short strategy. The Fund is managed by Antipodes applying the same investment strategy as it applies to the investment portfolio of Antipodes Global Investment Company Limited (ASX:APL).

The following charts and information are provided to compare the performance of Antipodes' global long-short strategy to the value index and other value-oriented peers as selected by Morningstar Direct.

Please note that the performance of the Fund differed from the performance of APL's NTA by an amount of 3.4% since inception due to differences in management fees, taxes, costs and portfolio position weights.

Source: Morningstar Direct

As at Oct 2020


Note: For track record comparability, Class I returns are used for the Antipodes Global Fund - Long.



Cheap exposure to growth and quality

Global Long-Short

STYLE EXPOSURES - Percentile score of fully invested long and short books (50 = market median)



As at Sep 2020

Scores computed against global universe, MCAP > US\$1.5b. A percentile score of 100 represents the highest Growth/Resilience/Value (cheap) characteristics relative to the market. Source: Antipodes Partners.

*Denotes the median multiple, long term growth rate, and Net Debt/EBITDA of stocks with similar Value, Growth and Quality scores respectively.





Q&A





Thank you for joining us

APL SHAREHOLDER ENQUIRIES

For general information about your shareholding please contact the share registry Boardroom:

T: 1 300 737 760

E: enquiries@boardroomlimited.com.au

For investment enquiries please contact Pinnacle:

T: 1 300 010 311

E: invest@antipodespartners.com

Disclaimer

Note: Past performance is not a reliable indicator of future performance.

Antipodes Partners Limited ABN 29 602 042 035 AFSL 481580 ('Antipodes Partners', 'Antipodes') is the investment manager of Antipodes Global Investment Company Limited ABN 38 612 843 517 ('APL' or the 'Company').

While APL and Antipodes Partners believe the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk.

Subject to any liability which cannot be excluded under the relevant laws, APL and Antipodes Partners disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information.

Any opinions and forecasts reflect the judgment and assumptions of Antipodes Partners, APL and their representatives on the basis of information at the date of publication and may later change without notice.

Disclosure contained in this communication is for general information only and was prepared for multiple distribution. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. The information in this communication has been prepared without taking account of any person's objectives, financial situation or needs.

Unless otherwise specified, all amounts are in Australian Dollars (AUD).

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from APL and Antipodes Partners.

